Zacks Research Estimates Prothena FY2027 Earnings

Prothena Co. plc (NASDAQ:PRTA - Free Report) - Equities researchers at Zacks Research issued their FY2027 earnings per share (EPS) estimates for Prothena in a research report issued on Wednesday, March 12th. Zacks Research analyst E. Bagri anticipates that the biotechnology company will post earnings per share of ($3.04) for the year. The consensus estimate for Prothena's current full-year earnings is ($4.04) per share.

Prothena (NASDAQ:PRTA - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($1.08) earnings per share for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.06). Prothena had a negative net margin of 90.50% and a negative return on equity of 22.67%. The firm had revenue of $2.12 million during the quarter, compared to analysts' expectations of $7.53 million.

A number of other analysts have also commented on the company. Oppenheimer increased their price objective on Prothena from $58.00 to $62.00 and gave the company an "outperform" rating in a research note on Friday, February 7th. Bank of America decreased their price objective on Prothena from $26.00 to $22.00 and set a "neutral" rating on the stock in a research note on Thursday, December 19th. Chardan Capital reaffirmed a "buy" rating and set a $40.00 price objective on shares of Prothena in a research note on Friday, February 21st. Royal Bank of Canada decreased their price objective on Prothena from $24.00 to $20.00 and set a "sector perform" rating on the stock in a research note on Friday, February 21st. Finally, Piper Sandler increased their price objective on Prothena from $94.00 to $110.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $55.00.

Remove Ads

Prothena Trading Down 6.6 %

Shares of PRTA stock traded down $0.91 during mid-day trading on Friday, reaching $12.83. The stock had a trading volume of 479,927 shares, compared to its average volume of 485,556. Prothena has a 12-month low of $11.70 and a 12-month high of $26.75. The company has a market cap of $690.60 million, a P/E ratio of -5.58 and a beta of -0.02. The business has a 50-day simple moving average of $14.41 and a 200 day simple moving average of $16.04.

Institutional Trading of Prothena

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PRTA. GSA Capital Partners LLP purchased a new stake in Prothena in the 3rd quarter valued at about $484,000. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Prothena by 8.6% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 122,492 shares of the biotechnology company's stock valued at $2,049,000 after buying an additional 9,666 shares during the period. Intech Investment Management LLC purchased a new stake in shares of Prothena during the 3rd quarter worth about $210,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Prothena during the 3rd quarter worth about $432,000. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Prothena by 3.8% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 86,071 shares of the biotechnology company's stock worth $1,440,000 after purchasing an additional 3,163 shares during the period. Hedge funds and other institutional investors own 97.08% of the company's stock.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.